2023
Pulmonary Function and Quality of Life in Aging Men With and Without HIV from the Multicenter AIDS Cohort Study
Abdo M, Kunisaki K, Morris A, Stosor V, Chang D, D'Souza G, Crothers K, Abdel-Maksoud M, DiGuiseppi C, Brown T, Erlandson K, MaWhinney S. Pulmonary Function and Quality of Life in Aging Men With and Without HIV from the Multicenter AIDS Cohort Study. AIDS Research And Human Retroviruses 2023, 39: 621-632. PMID: 37276144, PMCID: PMC10712368, DOI: 10.1089/aid.2023.0001.Peer-Reviewed Original ResearchConceptsPulmonary impairmentPulmonary functionOdds ratioMedian age 57 yearsMulticenter AIDS Cohort StudyGreater respiratory impairmentPulmonary function impairmentImpaired pulmonary functionAge 57 yearsHealth-related qualityLower physical HRQoLRespiratory health statusAIDS Cohort StudyCohort study dataQuality of lifeHRQoL scoresCohort studyLower HRQoLPhysical HRQoLHIV serostatusAdjusted analysisFunction impairmentRespiratory impairmentMmHg decreaseRespiratory health
2019
Phase I study of pembrolizumab in people with HIV and cancer.
Uldrick T, Goncalves P, Abdul Hay M, Claeys A, Emu B, Ernstoff M, Fong L, Kaiser J, Kohrt H, Lacroix A, Lee S, Lundgren L, Lurain K, Parsons C, Peeramsetti S, Ramaswami R, Sharon E, Wang C, Yarchoan R, Cheever M. Phase I study of pembrolizumab in people with HIV and cancer. Journal Of Clinical Oncology 2019, 37: 2500-2500. DOI: 10.1200/jco.2019.37.15_suppl.2500.Peer-Reviewed Original ResearchAdverse eventsNon-Hodgkin lymphomaAntiretroviral therapyViral loadClinical benefitAnti-PD-1/PD-L1 therapyCD4 cells/μL.Elevated AST/ALTMedian age 57 yearsMulticenter phase 1 trialTreatment-emergent adverse eventsEmergent adverse eventsHBV/HCVSquamous cell skinPD-L1 therapyAge 57 yearsHIV viral loadAST/ALTPhase 1 trialCells/Cells/μL.Multicentric Castleman's diseaseAppropriate eligibility criteriaImmuno-oncology studiesNumber of cancersThe Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry
Gul B, Lansky A, Budoff MJ, Sharp D, Maniet B, Herman L, Kuo JZ, Huang L, Monane M, Ladapo JA. The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry. Journal Of Women's Health 2019, 28: 728-735. PMID: 30653377, PMCID: PMC6537117, DOI: 10.1089/jwh.2018.7203.Peer-Reviewed Original ResearchConceptsObstructive coronary artery diseaseCoronary artery diseaseFurther cardiac evaluationCardiac evaluationArtery diseaseClinical utilityStable obstructive coronary artery diseaseMajor adverse cardiac eventsMedian age 57 yearsMedian body mass indexAdverse cardiac eventsAge 57 yearsManagement of womenBody mass indexCommunity-based registryPrimary care practicesPrecision medicine testsGene expression scoreCardiac referralHypertension presentSymptoms SuggestiveCardiac eventsClinical characteristicsMass indexStudy cohort
2012
ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).
Marur S, Lee J, Cmelak A, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). Journal Of Clinical Oncology 2012, 30: 5566-5566. DOI: 10.1200/jco.2012.30.15_suppl.5566.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaInduction chemotherapySquamous cell carcinomaQuality of lifeCell carcinomaDay 1Primary siteMedian age 57 yearsResectable squamous cell carcinomaPhase II clinical trialCetuximab loading doseCisplatin 75mg/Pack-years smokingStandard-dose RTTumor stage T1Age 57 yearsHuman papillomavirus infectionPhase II trialProgression-free survivalExpression of biomarkersLow-dose radiationClinical CRRT armTarget accrualToxic regimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply